Last updated: 2026-09-05 14:19:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Zura Bio Limited (ZURA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $6.22, with a market capitalization of $543.35M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.88 to $7.44. This page covers its latest market performance, valuation, price trends and company information.
$543.35M | |
$5.92 | |
$37.55 | |
$0.97 | |
$5.88 | |
1.10M | |
-- | |
-- | |
$7.44 | |
$1.88 | |
-- | |
-- |
Zura Bio Limited (ZURA) last closed at $5.88 as of 2026-09-04 23:54:00, unchanged from the previous close of $5.88.
During the latest regular trading session, ZURA traded between $0.97 and $37.55, with a volume of 1.10M shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Zura Bio Limited (ZURA) moved from $5.68 to $6.22, representing a gain of 9.42% ($0.54).
The stock traded between $5.63 and $6.26 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 1.37 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 78.0%
ZURA is currently trading at $6.22, placing it 78.0% of the way from its 52-week low of $1.88 to its 52-week high of $7.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 40 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Zura Bio Limited (ZURA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.